Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 9 Mar 2021 |
| Transactions in connection with share buy-back program | 8 Mar 2021 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 7 Mar 2021 |
| Genmab A/S has published its Articles of Association | 3 Mar 2021 |
| Genmab A/S has published its Articles of Association | 2 Mar 2021 |